In yesterday’s Wall Street session, Lantheus Holdings Inc. (NASDAQ:LNTH) shares traded at $73.06, down -10.71% from the previous session.
As of this writing, 8 analysts cover Lantheus Holdings Inc. (NASDAQ:LNTH). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $130.00 and a low of $110.00, we find $125.00. Given the previous closing price of $81.82, this indicates a potential upside of 52.77 percent. LNTH stock price is now -16.34% away from the 50-day moving average and -0.45% away from the 200-day moving average. The market capitalization of the company currently stands at $4.85B.
There are 0 analysts who have given it a hold rating, whereas 8 have given it a buy rating. Brokers who have rated the stock have averaged $121.75 as their price target over the next twelve months.
With the price target of $120, JMP Securities recently initiated with Mkt Outperform rating for Lantheus Holdings Inc. (NASDAQ: LNTH).
In other news, Sabens Andrea, Chief Accounting Officer sold 1,752 shares of the company’s stock on Jul 19. The stock was sold for $159,209 at an average price of $90.87. Upon completion of the transaction, the Chief Accounting Officer now directly owns 59,767 shares in the company, valued at $4.37 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 18, President Blanchfield Paul sold 1,500 shares of the business’s stock. A total of $146,895 was realized by selling the stock at an average price of $97.93. This leaves the insider owning 92,743 shares of the company worth $6.78 million. Insiders disposed of 388,567 shares of company stock worth roughly $28.39 million over the past 1 year. A total of 1.60% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in LNTH stock. A new stake in Lantheus Holdings Inc. shares was purchased by NORGES BANK during the first quarter worth $65,058,000. HOLOCENE ADVISORS, LP invested $39,505,000 in shares of LNTH during the first quarter. In the first quarter, BOSTON PARTNERS acquired a new stake in Lantheus Holdings Inc. valued at approximately $24,485,000. EAGLE HEALTH INVESTMENTS LP acquired a new stake in LNTH for approximately $20,807,000. PORTOLAN CAPITAL MANAGEMENT, LLC purchased a new stake in LNTH valued at around $16,678,000 in the second quarter. In total, there are 525 active investors with 101.30% ownership of the company’s stock.
Thursday morning saw Lantheus Holdings Inc. (NASDAQ: LNTH) opened at $74.35. During the past 12 months, Lantheus Holdings Inc. has had a low of $47.46 and a high of $100.85. As of last week, the company has a debt-to-equity ratio of 1.25, a current ratio of 2.80, and a quick ratio of 2.60. The fifty day moving average price for LNTH is $86.82 and a two-hundred day moving average price translates $73.41 for the stock.
The latest earnings results from Lantheus Holdings Inc. (NASDAQ: LNTH) was released for Mar, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at $1.47, beating analysts’ expectations of $1.26 by 0.21. This compares to $0.61 EPS in the same period last year. The net profit margin was -1.70% and return on equity was -3.40% for LNTH. The company reported revenue of $300.78 million for the quarter, compared to $208.88 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 44.0 percent. For the current quarter, analysts expect LNTH to generate $305.75M in revenue.
Lantheus Holdings Inc.(LNTH) Company Profile
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent. The company also offers AZEDRA, a radiotherapeutic therapy; Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; PNT2002 for pre-chemotherapy patients; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; and PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer. The company serves hospitals, independent diagnostic testing facilities, government facilities, integrated delivery networks, radiopharmacies, clinics, distirbutors, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; and FUJIFILM. The company was founded in 1956 and is based in Bedford, Massachusetts.
